| Date Filed | Type | Description |
| 10/03/2023 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 7,172 shares
@ $0.6199, valued at
$4.4k
Exercised 24,474 restricted stock units
@ $0 |
|
| 07/03/2023 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 10,269 shares
@ $0.855, valued at
$8.8k
Exercised 35,039 restricted stock units
@ $0 |
|
| 04/04/2023 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 4,286 shares
@ $1.39, valued at
$6k
Exercised 13,911 restricted stock units
@ $0 |
|
| 02/03/2023 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Granted 221,839 options
@ $3.16, valued at
$701k
Granted 169,012 restricted stock units
@ $0 |
|
| 01/03/2023 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 4,814 shares
@ $2.37, valued at
$11.4k
Paid exercise price by delivering 2,327 shares
@ $2.37, valued at
$5.5k
Exercised 13,912 restricted stock units
@ $0
Exercised 6,723 restricted stock units
@ $0 |
|
| 10/03/2022 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 4,077 shares
@ $1.52, valued at
$6.2k
Exercised 13,911 restricted stock units
@ $0 |
|
| 07/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/01/2022 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 1,155 shares
@ $2.55, valued at
$2.9k
Exercised 3,941 restricted stock units
@ $0 |
|
| 02/04/2022 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Granted 211,018 options
@ $2.8, valued at
$590.9k
Granted 159,522 restricted stock units
@ $0 |
|
| 01/04/2022 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 2,327 shares
@ $3.21, valued at
$7.5k
Exercised 6,724 restricted stock units
@ $0 |
|
| 01/04/2022 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 1,364 shares
@ $3.21, valued at
$4.4k
Exercised 3,941 restricted stock units
@ $0 |
|
| 10/01/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/02/2021 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics|
Txns:
| Paid exercise price by delivering 2,310 shares
@ $5.89, valued at
$13.6k
Exercised 7,883 restricted stock units
@ $0 |
|
| 02/16/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/28/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/20/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/20/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/27/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/08/2018 |
3
| Tactic Pharma LLC (Chief Scientific Officer) has filed a Form 3 on Monopar Therapeutics |
| 01/08/2018 |
3
| Robinson Chandler (CEO) has filed a Form 3 on Monopar Therapeutics |